Hongbo Pharmaceutical

Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. is a rapidly developing enterprise specializing in new drug R&D services and API production. Since its establishment in December 2007, the company has been driven by technological innovation, aiming to create a distinctive "intelligence-based" innovative enterprise. It actively engages in comprehensive cooperation with clients and business partners, striving to become a leading enterprise in new drug creation services, API process innovation research, production, and sales.
Hongbo Pharmaceutical is headquartered in the eastern area of Zhangjiang High-Tech Industrial Park, Pudong New Area, Shanghai, with nearly 22,000 square meters of office space, laboratories, and advanced equipment. Since its inception, the company has focused on creating a safe, comfortable, and scientific working environment for employees. It currently boasts various experimental and testing equipment, including NMR, SFC, HPLC, chiral-HPLC, LC-MS, LC-MS/MS (API4000), IR, UV, GC, GC-MS, normal/reverse-phase preparative chromatography, microwave synthesizers, and parallel synthesizers. As a high-tech enterprise, this high-quality research environment ensures the efficient operation and scientific achievements of Hongbo Pharmaceutical's R&D departments.
Hongbo Zhiyuan (Kaiyuan) Pharmaceutical, located in Kaiyuan City, Liaoning Province, serves as the production base. Covering an area of 150,000 square meters, it features plants, facilities, and testing systems that comply with current GMP standards. It primarily focuses on the R&D, production, and sales of high-end chemical APIs and intermediates at the forefront of international trends. Current products include ticagrelor, peramivir, velpatasvir, sofosbuvir, etc. The base has obtained the EU COS certificate and multiple international high-end certifications, and maintains long-term cooperation with several well-known foreign enterprises such as Pfizer (USA), Abbott (USA), Novartis (Switzerland), Sanofi (France), Chemo (Italy), TEVA (Israel), Dr. Reddy's and Cipla (India), demonstrating immense potential for sustained growth.
The company currently employs nearly 850 people. In 2010, it was recognized as a technology-advanced service enterprise, and from 2014 to 2017, it was consecutively rated as a high-tech enterprise. Dr. Chen Ping, CEO, and Dr. Cai Zhenwei, Senior Vice President of Medicinal Chemistry, are both seasoned experts in medicinal chemistry. For their contributions to a class of anti-cancer new drugs, they received the Thomas Edison New Drug Invention Patent Award in the United States in 2008 and 2011, respectively.
Hongbo Pharmaceutical emphasizes a corporate culture of "science-oriented and continuous innovation," which is integrated into its management systems, talent development, and team building. In addition to focusing on scientific and experimental skills development, the company organizes annual parties, quality development training, group trips, birthday celebrations, and various cultural and sports activities. It also establishes a special fund for team building. These activities not only provide employees with vertical and horizontal communication opportunities but also enhance their sense of belonging and teamwork awareness.